Table 3 Myelosuppression-related toxicities and early mortality by treatment regimen.

From: Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

 

Gustave Roussy Cohort

“7 + 7”

n = 82

MDACC Cohort

“std-HMA/VEN”

n = 166

p

Cycle 1 (n = 248)

 Febrile neutropenia

39/82 (48)

91/166 (55)

0.282

 Required any pRBC

65/77 (84)

137/166 (83)

0.715

 # units pRBC/patient

6 [0–48]

7 [0–31]

0.426

 Required any platelets

48/77 (62)

128/166 (77)

0.017

 # units platelets/patient

2 [0–51]

4 [0-50]

0.083

Cycle 2 (n = 200)

 Febrile neutropenia

24/73 (33)

42/127 (33)

0.978

 Required any pRBC

31/59 (53)

71/127 (56)

0.668

 Required any platelets

17/59 (29)

43/127 (34)

0.493

Early Mortality

 4-week mortality

2 (2)

9 (5)

0.347

 8-week mortality

5 (6)

26 (16)

0.032

  1. Data displayed as n (%) or median [range].
Back to article page